Nicht aus der Schweiz? Besuchen Sie lehmanns.de

Epigenetics and Disease

Pharmaceutical Opportunities

Susan M. Gasser, En Li (Herausgeber)

Buch | Softcover
X, 270 Seiten
2012 | 2011
Springer Basel (Verlag)
978-3-0348-0305-2 (ISBN)

Lese- und Medienproben

Epigenetics and Disease -
CHF 389,95 inkl. MwSt
  • Versand in 10-14 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
Epigentic alterations, unlike genetic, are, in principle, amenable to pharmacological intervention, and a few of those drugs are currently undergoing clinical trial. This volume highlights the results of those studies.

Epigenetics has emerged recently as an important area of molecular biological studies. Epigenetic modifications lead to potentially heritable but reversible alterations in the expression of genes that determine cell fate. Epigenetic misregulation is thus often linked to degenerative diseases, cancer and neuronal disorders.Recent biomedical interest in this regulatory system stems from the fact that epigenetic, in contrast to genetic, alterations are in principle amenable to pharmacological intervention. A few epigenetically active drugs, for example histone deacetylase inhibitors (HDACi) and DNA methyltransferase (DNMT) inhibitors, have been approved by FDA for treatment of cancers such as CTCL, MDS, and AML.This volume explores the scientific background for clinical applications of epigenetically active drugs. Included are descriptions of epigenetic controls over gene expression, the post-transcriptional silencing of genes by RNA interference (RNAi) and microRNAs, as well as new findings from stem cell research which are relevant to pharmacological applications.

DNA Methylation and Cancer.- Genome-wide Epigenetic Modifications in Cancer.- DNA Repair and the Control of DNA Methylation.- Errors in Erasure: Links Between Histone lysine Methylation Removal and Disease.- Histone Modifications in Cancer Biology and Prognosis.- Dynamics of Histone Lysine Methylation: Structures of Methyl Writers and Eraser.- Epigenetic Mechanisms of Mental Retardation.- Histone and DNA Modifications in Mental Retardation.- HDAC Inhibitors and Cancer Therapy.- Epigenetic Mechanisms in Acute Myeloid Leukemia.- The Liver-Specific MicroRNA miR-122: Biology and Therapeutic Potential.- Witold Filipowicz and Helge Großhans.- Transcriptional Regulatory Networks in Embryonic Stem Cells.- Small Molecules in Cellular Reprogramming and Differentiation.

Erscheint lt. Verlag 12.3.2012
Reihe/Serie Progress in Drug Research
Zusatzinfo X, 270 p.
Verlagsort Basel
Sprache englisch
Maße 155 x 235 mm
Gewicht 430 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete
Studium 2. Studienabschnitt (Klinik) Humangenetik
Schlagworte Cancer • DNA Methylation • Epigenetik • Krankheit • neuronal disorders • Stem Cells • therapy
ISBN-10 3-0348-0305-2 / 3034803052
ISBN-13 978-3-0348-0305-2 / 9783034803052
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Eine sehr persönliche Geschichte | Der New York Times-Bestseller

von Siddhartha Mukherjee

Buch | Softcover (2023)
Ullstein Taschenbuch Verlag
CHF 30,75
Die revolutionäre Medizin von morgen (Lifespan)

von David A. Sinclair; Matthew D. LaPlante

Buch | Softcover (2020)
DuMont Buchverlag
CHF 22,40